| Literature DB >> 35234147 |
Jakub W Kaminski1, Laura Vera1, Dennis P Stegmann2, Jonatan Vering2, Deniz Eris1, Kate M L Smith1, Chia Ying Huang1, Nathalie Meier1, Julia Steuber2, Meitian Wang1, Günter Fritz2, Justyna A Wojdyla1, May E Sharpe1.
Abstract
Over the last two decades, fragment-based drug discovery (FBDD) has emerged as an effective and efficient method to identify new chemical scaffolds for the development of lead compounds. X-ray crystallography can be used in FBDD as a tool to validate and develop fragments identified as binders by other methods. However, it is also often used with great success as a primary screening technique. In recent years, technological advances at macromolecular crystallography beamlines in terms of instrumentation, beam intensity and robotics have enabled the development of dedicated platforms at synchrotron sources for FBDD using X-ray crystallography. Here, the development of the Fast Fragment and Compound Screening (FFCS) platform, an integrated next-generation pipeline for crystal soaking, handling and data collection which allows crystallography-based screening of protein crystals against hundreds of fragments and compounds, at the Swiss Light Source is reported. open access.Entities:
Keywords: FFCS; automation; fragment-based drug discovery; high throughput; protein crystallography; software
Mesh:
Substances:
Year: 2022 PMID: 35234147 PMCID: PMC8900825 DOI: 10.1107/S2059798322000705
Source DB: PubMed Journal: Acta Crystallogr D Struct Biol ISSN: 2059-7983 Impact factor: 7.652
Figure 1Schematic of the FFCS pipeline. Initial crystals are optimized in SWISSCI MRC-3 plates and tested for DMSO resilience. Plates are stored in Rock Imager systems at 4°C or 20°C and are imaged at regular intervals. Selected fragments are contactlessly transferred from small-volume stock solutions to preselected crystal drops with the Echo liquid-handling device. Subsequent semi-automated crystal harvesting, supported by the Crystal Shifter robot, allows the efficient freezing of soaked crystals.
Figure 2Schematic representation of the FFCS software suite. The user console allows the design and control of experiments via the FFCS GUI. Relevant experimental metadata are stored in the dedicated FFCS DB database and transferred directly via the network to Echo and Crystal Shifter controller PCs. Rock Maker and central general parallel file system (gpfs) data storages (shown in green) are mounted on the user console; gpfs data storage is also mounted on the beamline console.
Figure 3The FFCS GUI. (a) The startup view with a central popup message. Tabs representing steps of the FFCS campaign are enlarged for clarity. (b) The Soaking tab showing the status of a fragment-soaking step; the example here is from the FFCS endothiapepsin campaign.
Figure 4The Xi GUI showing an endothiapepsin crystallization drop. The red dot indicates the position selected for targeted acoustic delivery of a fragment dissolved in DMSO.
Figure 5FFCS campaign results from two collaborative projects. (a) Resolution histogram of project 1 data sets shows that most crystals diffracted to around 1.7 Å (total range of 1.3–2.4 Å). (b) Resolution histogram of project 2 data sets shows that most crystals diffracted to 1.5 Å (total range of 1.1–2.4 Å). (c)–(f) Examples of bound fragments. Fragments were automatically placed by FLYNN (https://www.eyesopen.com/) into the F o − F c electron density from dimple runs. The F o − F c electron density is shown in green at 1.5σ. The fragments are (c) CD04232, N-(2,6-difluorophenyl)acetamide, PDB entry 7qu0, (d) BTB00030, 3-[(furan-2-yl)methyl]-1-(2-methylphenyl)thiourea, PDB entry 7qty, (e) Z26333434, 4-[(1H-1,3-benzodiazol-1-yl)methyl]benzonitrile, PDB entry 7qu3 and (f) AC14079, 5-methyloxolan-2-one, PDB entry 7qu5. Figures were generated automatically with PyMOL (https://pymol.org/) by the evaluation pipeline.
Success rates of FFCS campaigns for two example collaborative projects
| Project 1 | Project 2 | |
|---|---|---|
| No. of crystals soaked | 561 (100%) | 543 (100%) |
| No. of crystals mounted | 545 (97%) | 543 (100%) |
| No. of crystals diffracting to ≤2.5 Å resolution | 505 (90%) | 412 (76%) |
| Data sets with | 41 (7.3%) | 68 (12.5%) |
| Verified protein–fragment complexes | 35 (6.2%) | 35 (6.4%) |